“When we own portions of outstanding businesses with outstanding managements, our favorite holding period is forever.”
— Warren Buffett
Merck & Co. stock has delivered strong long-term results when measured on a total return basis, with dividends playing a meaningful role in compounding investor returns. Looking back over the 20-year period beginning in August 2006, an initial $10,000 investment in shares of Merck & Co Inc (NYSE: MRK) would have grown substantially by late August 2026, assuming all dividends were reinvested.
That kind of long-horizon analysis is useful because it shifts attention away from short-term price volatility and toward the drivers that matter most over time: business durability, dividend income, reinvestment, and compounding. For a mature pharmaceutical company such as Merck, total return depends not only on share-price appreciation but also on the cumulative value of cash distributions over many years.
MRK 20-Year Return Details
| Start date: | 08/31/2006 |
|
|||
| End date: | 08/28/2026 | ||||
| Start price/share: | $38.69 | ||||
| End price/share: | $148.35 | ||||
| Starting shares: | 258.46 | ||||
| Ending shares: | 509.54 | ||||
| Dividends reinvested/share: | $40.43 | ||||
| Total return: | 655.90% | ||||
| Average annual return: | 10.64% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $75,593.41 | ||||
Over this 20-year period, MRK produced a 655.90% total return, turning $10,000 into $75,593.41 as of 08/28/2026. On an annualized basis, that equates to a 10.64% average annual return. These figures underscore the difference between simple price appreciation and full total return analysis, which captures both capital gains and reinvested dividends.
The calculations above were computed with the Dividend Channel DRIP Returns Calculator, assuming dividends were reinvested into additional shares at the closing price on the ex-dividend date.
How Much of Merck’s Return Came From Dividends?
Dividends were a material component of Merck’s long-term return profile. Over the period shown, the company paid $40.43 per share in cumulative dividends. Reinvestment increased the original share count from 258.46 shares to 509.54 shares, illustrating how a dividend reinvestment plan can compound results over time even when the underlying business moves through different market cycles.
That share-count growth matters. It means the ending value was driven not only by a higher stock price, but also by ownership of a meaningfully larger number of shares than at the outset. In long-duration equity investing, that mechanism is often one of the most powerful contributors to wealth creation.
Merck Yield and Yield on Cost
Using the most recent annualized dividend rate of $3.40 per share, MRK has a current yield of approximately 2.29% based on the ending share price of $148.35. Another useful metric is yield on cost, which measures the current annual dividend against the original purchase price rather than the current market price.
In this case, dividing the current annualized dividend of $3.40 by the initial share price of $38.69 produces a yield on cost of 8.79%. That figure is distinct from current yield: it does not indicate what a new buyer would earn today, but rather how the income stream has grown relative to the original capital committed two decades earlier.
What This 20-Year MRK Return Shows
Several conclusions emerge from Merck’s 20-year investment result:
- Long-term total return can differ materially from price return alone.
- Dividend reinvestment can significantly expand share ownership over time.
- Established dividend-paying companies can generate competitive compounding even through periods of sector and market volatility.
- Yield on cost can rise substantially when a company sustains and grows its dividend over many years.
For evaluating MRK or similar dividend stocks, the central question is not simply whether the stock price increased, but how the combination of dividends, reinvestment, and time affected the final outcome. Over this period, that combination proved highly effective.
